Merus N.V.
MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumorā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$96.63
Price-0.15%
-$0.14
1Y
Price
Market Cap
$7.328b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-733.0%
EBITDA Margin-786.2%
Net Profit Margin-821.7%
Free Cash Flow MarginRevenue
$51.174m
+46.7%
1y CAGR+12.3%
3y CAGR+6.7%
5y CAGREarnings
-$334.902m
-61.1%
1y CAGR-41.3%
3y CAGR-58.1%
5y CAGREPS
-$5.34
-59.4%
1y CAGR-24.6%
3y CAGR-35.6%
5y CAGRBook Value
$661.629m
$771.994m
Assets$110.364m
Liabilities$10.516m
DebtDebt to Assets
1.4%
-
Debt to EBITDAFree Cash Flow
-$317.874m
-69.5%
1y CAGR-30.2%
3y CAGR-62.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company